

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
Apotex Corp	60505627101	AZACITIDINE INJECTION	12/12/2023

Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally

Product launched at a price that is comparable to competitors.

The estimated volume of patients who may be prescribed the drug

32

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval

N

Date and price of acquisition if the drug was not developed by the manufacturer

--